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Early in 1967, preliminary reports were made from our institutions (Starzl, Marchioro et al. 
1967; Starzl, Porter et a/., 1967) of the first clinical use of heterologous antilymphocyte globu- 
lin (ALG). T h ~ s  immunosuppressive agent was prepared from the serum of horses that had 
been immunized against cadaveric lymphoid tissue, especially spleens (Iwasaki et al., 1967). 
It was added to therapy with standard anti-rejection drugs, azathioprine and prednisone, and 
its use was restricted to the first 4 postoperative months. The evidence then was that ALG 
was of value at least in avoiding some of the problen~s which were present early after renal 
homotransplantation. 
Because ALG was used only during the first months after transplantation, an important 
unanswered question was whether late rejection would be a serious problem after the foreign 
protein administration was stopped. Evidence is now available on this point since the survi- 
vors amongst the first 20 patients who received consanguineous homografts are 11 to 17 
months postoperative; their last ALG injections were 7 to 13 months ago. 
The present report will beconcerned with a summary follow-up of these early cases; a more 
detailed analysis is being published elsewhere (Starzl, Groth, Terasaki etal., 1968). Inaddition 
a brief description will be given of 4 patients who received orthotopic transplantation of 
cadaveric livers while under therapy with the same immunosuppressive regimen. 
RENAL HOMOTRANSPLANTATION 
Intramuscular globulin injections were given daily for 5 days before and for 2 weeks after 
transplantation, then every other day for 2 wceks, twice a week for 2 months, and once a 
week for a final month (Fig. 1). Azathioprine was administered indefinitely. Prednisone was 
added if rejection developed despite prior therapy with azathioprine and ALG, in some cases 
because of serologic evidence of a host antibody response to the horse protein (Fig. I), or in a 
few instances as a prophylactic immunosuppressive measure from the time of operation. 
After the 4 month course of ALG therapy had ended, the patients were watched closely for 
the appearance of delayed rejection. This complication, which was observed in only 2 of the 
first 20 cases, was treated by upward adjustments of the prednisone dosage (Fig. 1). 
Mortality 
The first 20 ALG-treated recipients of consanguineous homografts were operated upon 1 I to 
17 months ago. Nineteen (95%) are still alive with function of their original homografts. All 
are in excellent condition. The only death was the consequence of a surgical error (Starzl, 
Porter et al., 1967). 
* This work was supported by United States Public Health Service grants FOS-TW-1154, AM06283, 
AM 06344, H E  07735, AM 07772, A1 04152, FR 00051 and FR 00069. 
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Fig. I .  The course of a patient who received antilymphocyte globulin (ALG) before and for the first 
4 months after renal homotransplantation. The donor was an elder brother. There was a good 
histocompatibility match between donor and recipient. There was no early rejection. Pred- 
nisone therapy was started 40 days postoperatively because of the high rises in the serologic 
titers which warned against a possible anaphylactic reaction. Note the insidious onset of late 
rejection after cessation of globulin therapy. This was treated by increasing the maintenance 
dose of steroids. This delayed complication was seen in only 2 of the original 20 patients. (By 
permission of Surgery, Gynecology and Obstetrics, 1968, 126.) 
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Fig. 2. Survival curve of the first 20 recipients of renal homografts who were treated with antilympho- 
cyte globulin (ALG) conlpared to the survival of those patients in 3 previous series of con- 
sanguineous transplantations at our institutions. Follow-ups in the globulin-treated group are 
11 to 17 months. (By pern~ission of Surgery, Gynecology and Obstetrics, 1968, 126.) 
HETEROLOGOUS ALG IN HUMAN RENAL AND LIVER TRANSPLANTATION 
In Figure 2, these results are contrasted with those obtained in 3 previous consecutive 
series of 32, 14, and 25 similar patients treated with kidneys from related donors at  our 
institutions. In the past cases, there was a mortality during the same interval of follow-up of 
28 to 31%. 
Drug therapy and function 
The improved survival in the ALG-treated patients can most readily be explained by the fact 
that rejection could be controlled despite the use of reduced doses of the standard immuno- 
suppressive agents. As the earlier series were being compiled there was a progressive tendency 
to use smaller quantities of azathioprine in an effort to avoid bone marrow depression. This 
trend continued into the globulin-treated series (Fig. 3). 
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Fig. 3. Intrafamilial renal homotransplantation. The average azathioprine and prednisone doses per 
kg/day and the creatinine clearances for the first 16 postoperative weeks (shaded) and for the 
subsequent 6 months (solid). Shown are the retrospective control series 1-3, and the ALG 
series (Group 4). Inclusion in the analysis was contingent upon survival for 294 days, a condi- 
tion which was met with the highest regularity in the ALG patients. (By permission of Surgery, 
Gynecology and Obstetrics, 1968, 126.) 
In  the 3 consecutive retrospective series, the more cautious use of azatl~ioprine had ne- 
cessitated progressively increasing average doses of prednisone in order to  prevent rejection 
of the homografts. The latter trend was reversed in the ALG series (Fig. 3). The steroid doses 
in the first 4 months were the smallest of any of the groups, and in the ensuing 6 months 
these remained at  a low level. The latter was a particularly encouraging notation since ALG 
therapy had then been discontinued. 
The gain of treating these patients with smaller doses of standard immunosuppressive 
agents was not paid for with a loss of homograft function. The creatinine clearances (Fig. 3) 
and other measures of renal function in the ALG-treated patients compared favorably with 
those in the retrospective series during the first 4 months post-transplantation, and in the 
ensuing 6 months they were distinctly better (Fig. 3). The comparative data with prednisone 
dosages and creatinine clearances are presented on a week to week basis in Figure 4. 
In all the foregoing studies, inclusion of any patient in the statistical analysis was contin- 
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Fig. 4. Intrafamilial renal honiotransplantation. Average creatinine clearances and daily prednisone 
doses for the 19 of 20 globulin-treated patients who lived for at least 10 months after receipt of 
homografts from blood relatives. These results are compared with pooled data from the 50 
of 71 patients previously observed who had lived for this long after similar intrafamilial homo- 
transplantation. Note the superior function and the smaller steroid doses of the globulin- 
treated patients who, because of their greater incidence of survival, were a less highly selected 
group than the included recipients in the retrospective control series. (By permission of Surgery 
Gyfiecology and Obstetrics, 1968, 126.) 
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gent upon survival for at least 10 months. This requisite was met with a 95% frequency in the 
ALG series but far less uniformly in the other groups. The favorable showing of the globulin- 
treated patients was thus in spite of a bias which excluded a number of unfavorable cases 
from each of the retrospective control series. 
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From the survival data and functional analyses presented thus far, it could be concluded that 
considerable histoincompatibility can be overridden in intrafamilial homotransplantation 
with the described therapeutic regimen since these cases were not selected because of highly 
compatible donor-recipient antigen matches as determined by Terasalci et a/. (1967). Does 
this suggest that histocompatibility matching techniques are going to become less important? 
That question was reviewed by examining the courses during the first 63 postoperative days 
of the 19 recipients in the above described series plus those of 19 more patients subsequently 
treated with homografts from blood relatives. The 38 globulin-treated patients were divided 
into those who had excellent, fair, and poor histocompatibility matches with their donors. 
The results, which are described fully elsewhere (Starzl, Groth, Terasaki et a/ . ,  1968), showed 
that the best renal function was in the cases with the best matches and that, conversely, the 
smallest average steroid doses were required in these cases. Thus, the penalties of breeching 
histocompatibility barriers, even with the improved treatment program, were the need for 
more stringent therapy and the necessity of accepting somewhat poorer function, 
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Cadaveric renal trar~splantation 
The foregoing results all concern intrafamilial homotransplantation. They indicate that the 
use of ALG lias permitted a reduction in early mortality, that it has contributed to a very 
considerable overriding of histocompatibility barriers, and that the benefits conferred by 
having an improved early course outlast the period of globulin therapy. What effect will these 
developments have upon the field of cadaveric transplantation and upon the transplantation 
of other organs? Our experience is too small to permit decisive conclusions, but there seems 
little reason to doubt that improvements will be possible here also. 
We have done 6 cadaveric renal homotransplantations using globulin therapy, with follow- 
ups of 4 to 12 months. Two patients have died, both after receipt of kidneys from a common 
cadaveric donor, both as a result of multiple pulmonary emboli and both within one day of 
each other after 3% months. There was little or no evidence of rejection in either homograft 
despite the presence of very poor histocompatibility matches in both. Three of the other 4 
patients have from good to excellent function of their original cadaveric homografts. The 
fourth patient, who is 1 year postoperative, has a creatinine clearance of 10-20 ml/min. and a 
BUN of 60-80 mg%. 
Toxicity 
Pain at the site of ALG injection was almost invariable. A variety of systemic reactions were 
seen including fever, hives, and generalized skin rashes. Anaphylactic reactions have occurred 
in 20% of the patients, but these were managed without difficulty. An impending anaphylactic 
reaction could often be predicted by rises in the titers of host precipitins or hemagglutinins or 
by the development of positive skin tests to intradermal horse protein. 
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Fig. 5. Technique of orthotopic liver transplantation. Note that the celiac axis (or alternatively the 
common hepatic artery) of the homograft is anastomosed to the proper hepatic artery of the 
recipient. 
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The toxicity encountered with more than 2,000 injections of ALG in the first 53 cases has 
been reviewed elsewhere (Kashiwagi et al., 1968). There have been no deaths caused by this 
agent. Biopsies of the homografts after 4 months in the first 8 cases revealed no evidence of 
either Masugi or serum sickness nephritis when examined with immunofluorescence and 
ferritin-labeling antibody techniques (Starzl, Porter et a/., 1967). 
LIVER HOMOTRANSPLANTATION 
From 1963 to the spring of 1967, 7 attempts were made at orthotopic liver transplantation at 
our institutions. All of the patients died in 23 days or less. The many reasons for these failures 
have been cited elsewhere and suggestions made for their correction (Starzl, Brettschneider 
and Groth, 1967). Amongst the most hopeful signs was the possibility that ALG admini- 
stration might contribute to more incisive and less toxic immunosuppression. 
In July 1967, 2 children were treated with orthotopic liver homotransplantation (Fig. 5); 
the first had a hepatoma and the second had extrahepatic biliary atresia. On September 5 and 
October 8, 2 more girls with biliary atresia received the same procedure. All 4 patients are 
stillalive from 1 to 31/2months postoperatively. A detailed account of this recent series is being 
published (Starzl, Groth, Brettschneider et a[., 1968) but some editorial comments may be in 
order. 
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Fig. 6. Course after orthotopic liver transplantation in a 19 month old patient whose liver disease was 
hepatoma. The initial rises in SGOT and SGPT were due to ischemic damage. The high 
secondary increases occurred at the time a septic liver infarction was diagnosed. The septi- 
cemia, indicated by encircled crosses, was with E.coli or Aerobacter-Klebsiella. Her present 
condition is excellent. (By permission of Surgery, 1968, 63.) 
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Other improvements than those of immunosuppression were brought to  these cases. 
Every effort was made t o  minimize ischemic injury t o  the livers during the terminal course of 
the donors and during the normothermic postnlorten~ period. Moreover, the extirpated or- 
gans were subsequently kept in an extremely effective preservation unit (Brettschneider et al., 
1967) until the recipients were prepared. In every instance, good immediate function of the 
transplanted livers was obtained. 
Subsequently, adequate to  excellent liver function (Fig. 6) was retained in 3 of the 4 pa- 
tients. Relatively small doses of azathioprine and prednisone were used. ALG was given 
every postoperative day for 2 weeks and every third day thereafter (Fig. 6). 
The fourth patient had ALG stopped after 7 weeks because of the fear that a n  anaphylactic 
reaction was impending; the child had developed high titers of precipitating antibodies against 
horse protein and had periorbital edema with each injection. Within 2 weeks, severe rejection 
developed which could be controlled only by increasing the daily prednisone dose t o  20 to 60 
mg. 
A number of serious complications have been seen in one or  more of thesepatientsincluding 
paralysis of the right diaphragm, septicemia, the development of septic liver infarctions 
(Fig. 6), atelectasis, and pneumonitis. The fact that none proved lethal may in part be attri- 
butable to the fact that heavy immunosuppression with the standard immunosuppressive 
agents could be avoided. This was possible even thoughagood donor-recipient antigen match 
was present in only one case; in the other 3 there was at  least 1 breech of the major human 
histocompatibility antigens which were recently summarized by Terasaki e t  al. (1967). 
It  is, of course, too early to  speculate upon the ultimate fate of these patients. Even now, 
however, it is evident that their lives have been prolonged. They are the first exan~ples of 
extended survival after clinical homotransplantation of the liver. 
Sunrn~ary 
Horse antihuman-lymphocyte globulin (ALG) has been used as an adjuvant immunosuppres- 
sive agent for all recipients of renal homografts treated at  the University of Colorado in the 
last 17 months. There is evidence that the addition of ALG has permitted adequate control of 
rejection when used in combination with reduced quantities of azathioprine and prednisone, 
that the postoperative mortality has thereby been reduced, and that the risks of the repeated 
foreign protein therapy are not prohibitive. 
Four recipients of orthotopic liver homografts were recently treated with the same thera- 
peutic regimen. They are alive 31/2, 31/4, 2, and 1 months postoperatively. 
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